Adagio Medical Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Adagio Medical Holdings, Inc. (ADGM) on December 11, 2025. The report discloses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Appointment: Sean Salmon was appointed as a Class II director, with a term expiring at the 2026 annual meeting of stockholders.
- Committee Assignments: Mr. Salmon was appointed to the Audit Committee and the Compensation Committee.
Management Commentary and Risks
Background: Mr. Salmon, age 60, brings extensive experience from Medtronic, where he served as Executive Vice President and President of the Cardiovascular Portfolio (2021–2025) and previously led the Diabetes Operating Unit. He also held leadership roles at C.R. Bard and Johnson & Johnson.
Compensation and Indemnification: Mr. Salmon will receive compensation consistent with the Company's non-employee director policy. The Company entered into a standard indemnification agreement, which may require the Company to cover certain expenses, judgments, fines, and settlement amounts incurred by Mr. Salmon in connection with his service as a director.
Risks and Contingencies: The filing states there are no undisclosed arrangements or relationships requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the specific compensation amounts for non-employee directors in the definitive proxy statement filed on November 4, 2025.
- Confirm the impact of the new director's expertise on the Company's strategic direction for cardiovascular and diabetes markets.
- Review the terms of the standard indemnification agreement for potential liability exposure.